<DOC>
	<DOCNO>NCT02490787</DOCNO>
	<brief_summary>This trial conduct globally . The aim trial investigate safety , pharmacokinetics ( exposure trial drug body ) pharmacodynamics ( effect investigate drug body ) concizumab administer subcutaneously haemophilia A subject .</brief_summary>
	<brief_title>Trial Investigating Safety , Pharmacokinetics Pharmacodynamics Concizumab Administered Subcutaneously Haemophilia A Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Male subject diagnose haemophilia A without inhibitor present screen currently treat ondemand Subjects baseline level factor VIII equal 2 % base medical record Age 18 64 year inclusive , time signing informed consent Body weight 50 100 kg , inclusive Known suspect hypersensitivity trial product relate product Platelet count 50x10^9/L screen Any clinical sign know history thromboembolic event , subject consider high risk thromboembolic event judge investigator Subjects increase risk cardiovascular disease judge investigator</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>